ABEONA THERAPEUTICS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ABEONA THERAPEUTICS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $3.00M | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $837.0K | Mar 18, 2019 |
| FY2018 | Dec 31, 2016 | $889.0K | Mar 18, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.82M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $3.50M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.41M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $3.00M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $10.00M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $3.00M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $837.0K | Mar 16, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $837.0K | Mar 16, 2018 |
| FY2017 | Dec 31, 2016 | $889.0K | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.04M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $925.0K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $2.04M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $4.40M | Mar 26, 2014 |
| FY2012 | Dec 31, 2011 | $1.84M | Mar 20, 2013 |
| FY2011 | Dec 31, 2010 | $481.0K | Mar 23, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.18M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($63.73M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($54.19M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($39.70M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($84.94M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($84.23M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($16.43M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($17.37M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($23.92M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($18.56M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($89.45M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($64.21M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($47.14M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($50.92M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($89.84M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($81.42M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | ($16.41M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($17.65M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($23.98M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($19.05M) | Mar 16, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.81M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $34.36M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $31.09M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $28.97M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $38.73M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $30.14M | Mar 31, 2022 |
| FY2019 | Dec 31, 2019 | $9.61M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $10.92M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $16.31M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $11.74M | Mar 16, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.03M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $29.85M | Mar 17, 2026 |
| FY2014 | Dec 31, 2014 | $3.71M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $4.83M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $6.02M | Mar 26, 2014 |
| FY2012 | Dec 31, 2011 | $5.76M | Mar 20, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($76.33M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($56.02M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($37.01M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($43.48M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($65.67M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($35.02M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($62.82M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($39.11M) | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | ($22.66M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($13.01M) | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.98M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.45M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $331.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $130.0K | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $4.15M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $1.34M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.31M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $9.24M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $860.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $519.0K | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $219.57M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $108.93M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $64.00M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $64.21M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $79.59M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $151.20M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $223.38M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $174.40M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $178.77M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $111.06M | Mar 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.35M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $64.90M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $49.18M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $37.45M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $37.22M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $48.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $44.95M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $40.35M | Mar 16, 2020 |
| FY2018 | Jan 1, 2018 | $2.39M | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $8.67M | Mar 18, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $159.22M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $44.03M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $14.83M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $26.76M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $42.37M | Mar 18, 2024 |
| FY2022 | Dec 31, 2020 | $102.55M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $178.43M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $134.05M | Mar 24, 2021 |
| FY2019 | Jan 2, 2018 | $6.30M | Mar 16, 2020 |
| FY2018 | Jan 1, 2018 | $176.37M | Mar 18, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2020 | $32.47M | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | $32.47M | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $32.47M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $32.47M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $32.47M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $32.47M | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 30, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($742.08M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($813.26M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($749.52M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($695.34M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($655.64M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($570.70M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($486.47M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($410.19M) | Mar 16, 2020 |
| FY2019 | Jan 2, 2018 | $2.60M | Mar 16, 2020 |
| FY2018 | Jan 1, 2018 | ($353.52M) | Mar 18, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.44M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $23.36M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $14.47M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $14.22M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $32.94M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $12.60M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $129.26M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $18.75M | Mar 16, 2020 |
| FY2019 | Dec 31, 2017 | $137.75M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $69.14M | Mar 18, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.04M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $18.96M | Mar 17, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | (21) | Mar 29, 2023 |
| FY2014 | Dec 31, 2014 | (15) | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | 3 | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 26, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 18, 2024 |
| FY2014 | Dec 31, 2014 | (15) | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | 3 | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 26, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 55.04M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | 45.64M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | 26.52M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 17.72M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | 5.89M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 96.13M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 83.62M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 47.94M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 46.89M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 40.25M | Mar 16, 2018 |